Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen Targets Esmya With First European Rival

Executive Summary

Alvogen has gained multiple European approvals for a rival to Gedeon Richter’s Esmya through the decentralized procedure.

You may also be interested in...



Gedeon Richter Predicts Two-Year Wait To Refile Pegfilgrastim, But Teriparatide Is In The Wings

A timeline to refile, for a second time, its proposed biosimilar to Neulasta with the EMA and plans to launch its biosimilar to Eli Lilly’s Forsteo across the EU featured on Gedeon Richter’s full-year earnings call for 2018.

Esmya Review Held Back Gedeon Richter in First Half

Sales of the uterine fibroid therapy, Esmya, sharply declined during the first half of 2018 at Hungary's specialty pharmaceuticals company, but an EU review of a potential association between the drug and liver injury has now been completed.

Liver Damage Worries Lead To Further EU Restrictions On Richter’s Esmya

The European Medicines Agency’s pharmacovigilance committee has recommended more restrictions on the use of Richter’s Esmya because of concerns over the risk of serious liver damage.

Topics

Related Companies

UsernamePublicRestriction

Register

PS125133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel